Proton pump inhibitor–induced erythema dyschromicum perstans–like pigmentation

Gutiérrez, Daniel; Krueger, Loren; Tan, Audrey; Park, Joyce H.; Lipkin, George; Meehan, Shane A

doi:10.1016/j.jdcr.2019.06.014

Cited by 6 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 There are reports of EDP occurring after ingestion of ammonium nitrate, 2 following viral meningitis, 3 and occurring months to years after initiation of proton pump inhibitors. 4 Recently, morphea-like lesions have been reported following BoNT-A injections for facial rhytides. 5 These are characterized by atrophic plaques or depressions in the forehead appearing within a couple of weeks after neuromodulator injection and self-resolving within 3 months.…”

Section: Discussionmentioning

confidence: 99%

Erythema dyschromicum perstans following neurotoxin injection for facial rhytides

Pruneda,

Lankford,

Nguyen

et al. 2023

JAAD Case Reports

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Erythema dyschromicum perstans following neurotoxin injection for facial rhytides

Pruneda,

Lankford,

Nguyen

et al. 2023

JAAD Case Reports

View full text Add to dashboard Cite

“…Erythema dyschromicum perstans (EDP), also called ashy dermatosis, is an uncommon, slowly progressive dermatosis characterized by ash gray hyperpigmented macules of variable size and shape symmetrically distributed over the neck, trunk and proximal arms. 6 cases of EDP have been described so far; 4 cases following the use of omeprazole, 49,50 1 case with esomeprazole 51 and 1 case with lansoprazole 52 . The latency between drug initiation and onset of the skin rash ranged between 2 to 12 months.…”

Section: Miscellaneousmentioning

confidence: 99%

Dermatologic adverse reactions to proton‐pump inhibitors: A synthetized review

Salloum

Nasr

Maalouf

2020

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Proton‐pump inhibitors (PPIs) are one of the most prescribed drugs. Their dermatological adverse reactions are multiple and vary in severity. Aims This review discusses all reported cutaneous side effects of PPIs in order to help physicians understand them and provide appropriate management. Methods A thorough search of PubMed, Embase, and FDAAQ8 drugs websites was conducted. 56 articles including case reports, case series, and review articles of PPI‐induced cutaneous adverse reactions were selected. Data were recorded regarding patient age, gender, history, clinical manifestations, diagnostic tests, management, and clinical outcomes. Results PPI‐induced adverse skin reactions are mostly immunological and include both immediate and delayed‐type hypersensitivity reactions. These reactions are sometimes life‐threatening. All PPIs can induce immediate IgE‐mediated reactions. Most of previously published cases of delayed‐type hypersensitivity reactions have involved esomeprazole, omeprazole, and lansoprazole. Skin tests are helpful in confirming PPI‐induced hypersensitivity reactions and diagnosing potential cross‐reactivities. PPIs should also be added to our list of usual suspects when considering possible culprits for a new presentation of drug‐induced subacute lupus erythematosus. PPI‐related occupational contact dermatitis has also been numerously reported. Conclusion PPIs should be considered in our list of culprits when considering a patient with a cutaneous drug reaction, taking into account that these drugs can cause severe immunological manifestations.

show abstract

“…1 EDP occurs in both children and adults, has a higher frequency noted in women, and is common among Latin American, Asian, and Indian populations. [2][3][4] The cause remains largely unknown; however, proton pump inhibitors, 5 radioactive contrast, 6 hypothyroidism, vitiligo, 7 and parasitic and hepatitis C infections, 1 are among the associations with EDP.…”

Section: Introductionmentioning

confidence: 99%